Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Change in Cash: 2018-2025

Historic Change in Cash for Whitehawk Therapeutics (WHWK) over the last 8 years, with Sep 2025 value amounting to -$107.0 million.

  • Whitehawk Therapeutics' Change in Cash fell 909.29% to -$107.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 million, marking a year-over-year increase of 119.16%. This contributed to the annual value of -$34.2 million for FY2024, which is 243.36% down from last year.
  • As of Q3 2025, Whitehawk Therapeutics' Change in Cash stood at -$107.0 million, which was down 29.49% from -$82.6 million recorded in Q2 2025.
  • In the past 5 years, Whitehawk Therapeutics' Change in Cash ranged from a high of $198.8 million in Q1 2025 and a low of -$107.0 million during Q3 2025.
  • Moreover, its 3-year median value for Change in Cash was -$5.9 million (2023), whereas its average is -$104,727.
  • Its Change in Cash has fluctuated over the past 5 years, first crashed by 1,753.98% in 2024, then spiked by 2,283.08% in 2025.
  • Over the past 5 years, Whitehawk Therapeutics' Change in Cash (Quarterly) stood at -$12.4 million in 2021, then plummeted by 673.42% to -$95.8 million in 2022, then surged by 93.83% to -$5.9 million in 2023, then surged by 68.44% to -$1.9 million in 2024, then plummeted by 909.29% to -$107.0 million in 2025.
  • Its Change in Cash was -$107.0 million in Q3 2025, compared to -$82.6 million in Q2 2025 and $198.8 million in Q1 2025.